Journal Title
Acta Pharmaceutica Sinica B

ACTA PHARM SIN B

ISSN / eISSN
2211-3835 / 2211-3843
Aims and Scope
Acta Pharmaceutica Sinica B (APSB) is a bimonthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences — including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
Subject Area

PHARMACOLOGY & PHARMACY

CiteScore
19.40 View Trend
CiteScore Ranking
Category Quartile Rank
Pharmacology, Toxicology and Pharmaceutics - General Pharmacology, Toxicology and Pharmaceutics Q1 #1/79
Web of Science Core Collection
Science Citation Index Expanded (SCIE) Social Sciences Citation Index (SSCI)
Indexed -
Category (Journal Citation Reports 2023) Quartile
PHARMACOLOGY & PHARMACY - SCIE Q1
H-index
28
Country/Area of Publication
Netherlands
Publisher
Elsevier BV
Annual Article Volume
281
Open Access
YES
Contact
C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING, PEOPLES R CHINA, 100050
Verified Reviews
Note: Verified reviews are sourced from across review platforms and social media globally.
2021.6 ACS Nano tragedy of submission (2 accepted, 1 rejected), Argue got rejected, took half a year.
2022.2.19 Submit APSB
2022.2.24 Under Review
2022.3.11 Revision (The questions raised by the three reviewers were crucial, and they provided excellent constructive feedback. They were very professional and gave high praise. The quality of the paper also improved significantly.)
2022.4.7 Revision Submitted
2022.4.9-4.22 Status with editor-decision in progress-under review-review completed-decision nerve-wracking
2022.5.7 Accept
The speed was much faster compared to before. Thanks to all the editors and reviewers at APSB. I wish domestic journals continued to improve!
2022-05-07
The self-citation rate is calculated as a percentage based on (1 - IF without self-citation / IF). In 2021, the "without self-citation" component of this journal's SCI IF is definitely problematic and needs to be recalculated after the data is corrected. One can only wonder why Clarivate Analytics didn't perform any abnormal data validation for such a simple error...
2021-10-09

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started